BANSISONS TEA INDUSTRIES LTD.

Novyra Pharmachem Ltd has announced that its Board of Directors will convene on November 2, 2026. The primary agenda item is the consideration and approval of the Unaudited Financial Results for the second quarter ended September 30, 2026, along with the Auditor's Limited Review Report. The meeting will also address any other business as permitted by the Chairman.

Novyra Pharmachem Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is effective from October 1, 2026, and will remain in effect until 48 hours after the declaration of its Unaudited Financial Results for the Quarter ended September 30, 2026. The decision aligns with SEBI regulations on insider trading, prohibiting Promoters, Directors, KMPs, Insiders, Designated Persons, Connected Persons, and their immediate relatives from trading during this period. The company will announce the date of the Board Meeting to approve these results in due course.

Novyra Pharmachem Ltd has officially changed its company email ID as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The old email ID, bansisonstea@gmail.com, has been replaced with the new official ID, novyrapharmachemlimited@gmail.com. All future official communications and investor grievances should now be directed to the new email address. The company has requested stakeholders to update their records accordingly.

Bansisons Tea Industries Limited has officially changed its name to Novyra Pharmachem Limited, effective January 19, 2026. This rebranding signifies a strategic expansion into the pharmaceutical, life sciences, and contract services sectors, including APIs, bulk drugs, intermediates, and specialty chemicals. The company aims to establish advanced research labs, implement green chemistry, and offer CRO, CDMO services. The name change reflects this broadened business focus, and the company will update its records with statutory authorities and stock exchanges.

Novyra Pharmachem Limited (formerly Bansisons Tea Industries Ltd) announced its un-audited financial results for the quarter ended June 30, 2026. The company reported a net loss of ₹1.99 crore for the quarter. Revenue from operations stood at ₹172.61 crore. The company's board reviewed the business and approved the financial results along with auditors' limited reports. The meeting was held on August 14, 2026.

Bansisons Tea Industries Ltd (now Novyra Pharmachem Limited) announced its un-audited financial results for the quarter ended June 30, 2026. The Board of Directors considered and approved these results along with the Auditors' Limited Reports. The company operates across Pharma, Real Estate, and Tea Estate segments. The filing indicates a net loss for the quarter. The Board meeting was held on August 14, 2026.

Bansisons Tea Industries Ltd (now Novyra Pharmachem Limited) has announced a Board of Directors meeting scheduled for August 14, 2026. The primary agenda is to consider and approve the unaudited financial results for the quarter ended June 30, 2026, along with the Auditor's Limited Review Report. The meeting will be held at the company's registered office. Other business may be discussed with the Chairman's permission.

Bansisons Tea Industries Ltd has announced the closure of its trading window for dealing in the company's securities. This closure will be effective from Wednesday, July 1, 2026, and will remain in effect until 48 hours after the declaration of its Unaudited Financial Results for the Quarter ended June 30, 2026. The decision aligns with SEBI regulations concerning insider trading. Promoters, directors, KMPs, designated persons, connected persons, and their immediate relatives are prohibited from trading during this period. The company will announce the board meeting date for approving the financial results in due course.

Bansisons Tea Industries Ltd (now Novyra Pharmachem Limited) held its 39th Annual General Meeting (AGM) on June 25, 2026, via Video Conferencing. All resolutions presented, including the adoption of audited financial statements for the year ended March 31, 2026, the re-appointment of a director, and a scheme of capital reduction, were passed. The voting results, along with the Scrutinizer's Report dated June 26, 2026, have been filed. The meeting confirmed the successful passage of five resolutions.

Novyra Pharmachem Limited, formerly Bansisons Tea Industries Ltd, has filed its 39th Annual Report for the financial year 2025-2026. The report, in compliance with SEBI regulations, has been sent to shareholders and uploaded to the company's website. The filing also includes the notice for the 39th Annual General Meeting (AGM) scheduled for June 25, 2026, where audited financial statements and the re-appointment of a director will be considered.